die Strategie wurde COVID angepasst....
man wird wohl ein extensive Phexxi TeleContraception network haben.....
"we believe will speed access to and uptake of Phexxi" !!!!
dazu stellen die erstmal keine weiteren Sale Reps mehr ein....
"We believe this strategic move leverages our resources for maximum potential"
"So as you know, with social distancing and restrictions on nonessential in-person health care appointments, telemedicine has become the norm overnight for conducting annual well visits, preexisting conditions, billing prescriptions and even diagnosing illnesses or injuries, or in our case, the contraception that's needed by women. Research insights recently cited contraception as one of the fastest-growing therapeutic areas in the COVID-19 environment for telehealth, and we believe Phexxi is ideally suited for this virtual and telemedicine platform. It's easy to understand. It's easy to use. It has a very favorable safety profile, which equates to low risk for patients and prescribers."
"So here's how it's going to work. Working through a concierge service for patients, a woman will be able to connect through the Phexxi consumer website or online banners or even one of the existing telemedicine platforms and gain access to appropriate counseling by a registered nurse or other health care provider who can answer her questions, help her with insurance coverage or with the Phexxi co-pay card and connect her to a pharmacy that will deliver Phexxi right to her door. Or if she prefers, she can have a prescription available at her local neighborhood pharmacy."
" Consensus among payers is that as long as the cost of Phexxi is relatively equal to the annual cost of a branded monthly contraception, they expect to cover Phexxi. The research also supports earlier findings that payers expect Phexxi to be widely reimbursed at 0 co-pay as a covered benefit under the Affordable Care Act or ACA."
"So in summary, this research tells us that we are well poised for the launch of what I believe will be a game changer in this category."
"with the strategic decision to move the Phexxi commercial launch to early September and the related pause of sales force hiring until the third quarter, we are forecasting a cash burn of around $13 million to $15 million in the second quarter."
zum Thema PDLI gibt es auch was
"Finally, as most of you are aware, our former strategic investor, PDL Biosciences, is in the process of liquidating assets with the aim of distributing net proceeds to stockholders. PDL announced yesterday that its Board of Directors has approved a distribution of its 13.3 million shares of Evofem common stock to PDL stockholders through a onetime dividend, which is expected to close on May 21. We are pleased with this plan, which defers -- diversifies what was a highly concentrated position into a much broader shareholder base, and we look forward to welcoming and engaging with our new stockholders in the Evofem story""
"we are not competing with hormones. We are talking about a group of women who have already declared that they are beyond hormones. So in that regard, we're not really at all concerned about the fact. In fact, what it will is it'll heighten the level of volume around the question of what is an appropriate method of contraception for women."
"...that a woman who is going to use a patch is predominantly not the same woman who's going to be using Phexxi, and vice versa...."
Den Rest könnt Ihr ja mal selber lesen ...
finance.yahoo.com/news/...-earnings-conference-024451801.html